Business Context and Reporting Period
This Form 8-K Current Report was filed by Achieve Life Sciences, Inc. on December 9, 2024, regarding events occurring on December 5, 2024. The filing discloses the appointment of a new Chief Financial Officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Mark K. Oki as Chief Financial Officer and principal financial officer, effective December 5, 2024. Mr. Oki previously served as CFO of Aytu Biopharma, Inc. (2022–2024) and Vivus LLC (2015–2022).
Employment Agreement and Compensation Terms
- Base Salary: $450,000 annually.
- Bonus: Discretionary annual bonus up to 40% of base salary.
- Equity Awards:
- Option to purchase 72,000 shares of common stock (vesting: 1/3 on first anniversary, then monthly).
- 168,000 performance-based restricted stock units (vesting based on Board-established objectives).
- Severance Provisions:
- Termination without cause or resignation for good reason: 12 months of base salary plus healthcare coverage.
- Change in control: 24 months of base salary plus 24 months of average bonus earnings, plus healthcare coverage.
- Equity acceleration: 12 months of vesting upon standard termination; full acceleration upon change in control.
Investor Verification Checklist
- Verify the full text of the Employment Agreement when filed as an exhibit to the Form 10-K for the fiscal year ending December 31, 2024.
- Confirm the specific performance objectives required for the vesting of the 168,000 restricted stock units.
- Review the company's cash position to assess the impact of the new executive compensation package on liquidity.
- Monitor future filings for any changes to the Board of Directors or additional executive appointments.